Part4: Experimental Weight Loss Peptides and Drugs 2026 - Retatrutide, CagriSema
Deep dive into experimental and pipeline weight loss drugs in 2026. Retatrutide, CagriSema, Orforglipron, Mazdutide, Tesofensine, Bimagrumab, AOD9604.
Part4: Experimental Peptides & Next-Gen Weight Loss Drugs.
← Back to Index | ← Part3: GLP-1 Injections
Critical Warning: None of the drugs in this section should be self-administered. Many circulate on the “research chemical” gray market. Unverified peptides may be contaminated, misdosed, or completely fake. Wait for official regulatory approval.
1. Retatrutide — “Retta” (The Triple Threat)
Salt Name: Retatrutide (LY3437943) Developer: Eli Lilly Class: Triple GLP-1 / GIP / Glucagon Receptor Agonist Status: Phase 3 Clinical Trials (2026) Available in India: ❌ Not approved. Research chemicals exist on gray market — avoid.
What Makes It Different
Retatrutide targets three receptors simultaneously:
- GLP-1R — Appetite suppression, insulin, gastric emptying
- GIPR — Additional metabolic effects (same as Tirzepatide)
- Glucagon R — Directly increases metabolic rate, liver fat burning
The glucagon component is what makes Retatrutide exceptional. It essentially forces your liver to burn fat even while at rest.
Phase2 Trial Results (Published 2023, Phase3 ongoing)
| Dose | Duration | Weight Loss |
|---|---|---|
| 4mg weekly | 48 weeks | ~17% |
| 8mg weekly | 48 weeks | ~22% |
| 12mg weekly | 48 weeks | ~24% |
24% weight loss is unprecedented. For reference, bariatric surgery typically produces 25–30%.
Expected India Availability
- Phase 3 completion: 2026–2027
- FDA approval: Estimated 2027–2028
- India CDSCO approval: 2028–2029
- Indian generic: 2029–2030
Known Side Effects
- Nausea, vomiting (similar to other GLP-1-s)
- Increased heart rate (tachycardia) — more prominent than Semaglutide
- GI distress (diarrhea, constipation)
- Injection site reactions
- Potential gallbladder issues (rapid weight loss)
- Long-term safety: Unknown — still in trials
Verdict
Rating: Pending. ⏳ WAIT. The data is extraordinary. But it’s not approved yet. Do not buy “Retatrutide” from peptide websites — you don’t know what you’re actually getting. Wait for official approval.
2. CagriSema (Cagrilintide + Semaglutide)
Developer: Novo Nordisk Class: Long-acting Amylin Analogue + GLP-1 Agonist combination Status: Phase 3 (REDEFINE trials) / NDA filed December 2025 Available in India: ❌ Not yet
What is Cagrilintide?
Amylin is a hormone co-released with insulin that:
- Slows gastric emptying (complementary to GLP-1)
- Suppresses glucagon
- Acts on the brain’s area postrema (satiety center)
Cagrilintide is a long-acting amylin analogue. Combined with Semaglutide, it attacks obesity from two completely different biological pathways.
Phase3 Results (REDEFINE Program)
| Trial | Duration | Weight Loss |
|---|---|---|
| REDEFINE 1 | 68 weeks | ~22.7% |
| REDEFINE 2 (T2D) | 68 weeks | ~15.7% |
| REDEFINE 4 (vs Tirzepatide) | 40 weeks | Slightly below Tirzepatide (missed non-inferiority) |
Side Effects
- Injection site nodules (cagrilintide-specific)
- Nausea, vomiting (semaglutide component)
- Heart rate increase
- GI effects
Verdict: ⏳ WAIT. Very promising. Expected FDA approval late 2026. Will likely be available in India 2027–2028 at premium pricing.
3. Orforglipron (Foundayo) — The Oral Non-Peptide GLP-1
Developer: Eli Lilly Class: Oral Non-peptide GLP-1 Receptor Agonist Status: FDA Approved (early 2026) as “Foundayo” Available in India: ❌ Not yet approved by CDSCO
Why It’s Different from Rybelsus
Rybelsus (oral Semaglutide) is a peptide — it requires special formulation with a permeation enhancer (SNAC) and must be taken on an empty stomach 30+ minutes before eating.
Orforglipron is a small molecule (non-peptide). It:
- Can be taken with or without food
- More convenient absorption
- Once daily oral
Phase3 Results (ATTAIN trials)
- ~12.4% weight loss at 72 weeks (highest dose, 36mg)
- Slightly less than injectable Semaglutide
- More GI side effects vs Rybelsus in some comparisons
Side Effects
- Nausea, vomiting, diarrhea (GLP-1 class effects)
- Higher discontinuation rate due to GI effects vs. oral semaglutide in some analyses
Verdict: ⏳ PROMISING. Oral convenience is a massive advantage. India approval expected 2027. Once available, it will be the preferred starting option for needle-averse patients.
4. Mazdutide (The China Dual Agonist)
Developer: Innovent Biologics (China) Class: Dual GLP-1 / Glucagon Receptor Agonist Status: Approved in China (2025), Not FDA approved Available in India: ❌ No
Results
- 18.6% weight loss at 48 weeks (9mg dose)
- Strong liver fat reduction (good for NAFLD/NASH patients)
- Similar mechanism to Retatrutide (but only dual, not triple)
Expected Price in India (If Approved)
- Estimated Generic: rupees 5,000–rupees 10,000/month
- Competitive pricing due to Chinese manufacturing
Verdict: ⏳ WATCH. China approval is notable. FDA trial data emerging. If approved in India, could be a more affordable Tirzepatide alternative.
5. Tesofensine
Developer: NeuroSearch Class: Triple Monoamine Reuptake Inhibitor (Serotonin + Norepinephrine + Dopamine) Status: Phase3 Trials (EU, Latin America) Available in India: ❌ No
Mechanism
Tesofensine works differently from GLP-1 drugs — it acts on three neurotransmitter systems:
- Serotonin → satiety
- Norepinephrine → appetite suppression, thermogenesis
- Dopamine → reduced food reward
This makes it similar to older CNS stimulants but without the dependency risk of amphetamines (theoretically).
Phase2 Results
- 10.6–12.6% weight loss at 24 weeks
- Also increases resting metabolic rate (unlike GLP-1 drugs)
Side Effects
- Dry mouth
- Nausea
- Increased heart rate
- Insomnia
- Potential for anxiety and mood effects
- Cardiovascular effects at higher doses need monitoring
Verdict: ⏳ INTERESTING. Unique mechanism — especially valuable because it raises metabolism while cutting appetite. Unlike GLP-1s, it doesn’t cause muscle loss (theoretically). Pending more safety data.
6. Bimagrumab (The Muscle Preserver)
Developer: Novartis / 23andMe Class: Anti-Activin Type II Receptor Monoclonal Antibody Status: Phase2 trials (combination with Semaglutide) Available in India: ❌ No
Why It’s Unique
GLP-1 drugs are notorious for causing muscle loss alongside fat loss. Bimagrumab attacks a completely different pathway:
- Blocks myostatin (a protein that inhibits muscle growth)
- Blocks activin signaling → muscle growth and fat breakdown triggered simultaneously
In trials combining Bimagrumab + Semaglutide:
- Fat mass decreased by ~20%
- Lean muscle mass INCREASED
- “High-quality” weight loss — only losing fat, gaining or maintaining muscle
This is potentially revolutionary for older adults and athletes who fear muscle wasting from GLP-1 drugs.
Verdict: ⏳ REVOLUTIONARY POTENTIAL. Not available yet but watch this space. Could become a required add-on to GLP-1 therapy.
7. Setmelanotide (Imcivree)
Salt Name: Setmelanotide Developer: Rhythm Pharmaceuticals Class: MC4 Receptor Agonist Status: FDA Approved (for specific genetic obesity only) Available in India: ⚠️ Very limited, specialty import only Price in India: rupees 50,000–rupees 1,00,000+ per unit
Who It’s For
ONLY for people with specific rare genetic mutations:
- POMC deficiency
- PCSK1 deficiency
- LEPR deficiency
- Bardet-Biedl syndrome
NOT for general obesity. This drug targets the MC4 receptor in the brain’s hunger regulation pathway that is genetically broken in these conditions.
Verdict: ❌ NOT FOR GENERAL USE. Specialized genetic therapy. Extraordinary cost.
8. AOD-9604 (Anti-Obesity Drug Fragment)
What it is: A fragment of human growth hormone (HGH) — specifically amino acids 176-191 Mechanism: Stimulates fat breakdown (lipolysis) without the insulin resistance or muscle-building effects of full HGH Price in India: rupees 2,000–rupees 8,000 for a vial (grey market peptide sellers) Evidence: Passed Phase2 trials for obesity (2001–2007) but failed Phase3. Not approved. Reality: Produces ~4-6% weight loss in studies, but long-term safety unknown. Risks: Unregulated product. Quality varies wildly. Contamination risk. Verdict: ⚠️ AVOID until regulated. Interesting mechanism, but not worth the risks of unverified products.
9. BPC-157 (Body Protection Compound)
What it is: Synthetic peptide derived from gastric juice protein Weight Loss Effect: None directly Use in stacks: Sometimes taken alongside GLP-1s to protect the gut lining from GI side effects Price: rupees 3,000–rupees 10,000 for 10mg vial Verdict: ⚠️ Unregulated. Limited human evidence. May help with gut health but no direct weight loss.
10. CJC-1295 + Ipamorelin
What it is: Growth hormone releasing peptide combination Claimed effect: Increases HGH → fat loss + muscle gain Price: rupees 5,000–rupees 15,000 for kit (grey market) Reality: Not proven for weight loss. Risk of insulin resistance with long-term use. Verdict: ❌ NO. Unregulated HGH stimulation is dangerous long-term.
11. Tirzepatide + Cagrilintide (Triple Stack)
Developer: Experimental combinations being studied Class: GLP-1 + GIP + Amylin triple mechanism Status: Pre-clinical / Early Phase1 Available in India: ❌ Absolutely not
The Concept
Combining:
- Tirzepatide (GLP-1 + GIP) — 20-22% weight loss
- Cagrilintide (Amylin) — Additional 2-3% weight loss
Theoretical weight loss: 25-28% — approaching bariatric surgery results.
Status
- Still in animal/early human trials
- Lilly and Novo Nordisk both researching combinations
- Expected timeline: 2029–2032 for approval
Verdict: ⏳ WAIT. Theoretical potential is enormous, but 5+ years away from market.
12. Semaglutide + Litaglutide (Dual Amylin)
Developer: Novo Nordisk (Research) Class: GLP-1 + Amylin dual agonist Status: Phase1/2 Trials Available in India: ❌ No
How it Differs from CagriSema
- CagriSema: Semaglutide + Long-acting Cagrilintide
- This combo: Semaglutide + Short-acting Litaglutide
Short-acting amylin may have:
- Better tolerability (less nausea)
- More natural feedback mechanism
- Lower cost (simpler molecule)
Expected Results
- ~18-21% weight loss (between Semaglutide and Tirzepatide)
- Better than CagriSema for some patients (less injection site nodules)
Verdict: ⏳ WATCH. Earlier stage than CagriSema but potentially better tolerated.
13. TB-403 (Anti-Myostatin Antibody)
Developer: Novartis / 23andMe Class: Anti-Activin Type IIB Receptor Monoclonal Antibody Status: Phase2 Trials (combination with Semaglutide) Available in India: ❌ No
The Science
Similar to Bimagrumab but more targeted:
- Blocks ActRIIB receptor specifically
- Increases muscle mass significantly
- Enhances fat loss synergistically with GLP-1s
Phase2 Results (with Semaglutide)
- Fat mass: -25% (vs. -20% with Semaglutide alone)
- Lean mass: +5% (vs. -2% with Semaglutide alone)
- “High-quality” weight loss with muscle gain
Verdict: ⏳ REVOLUTIONARY POTENTIAL. Still 3-5 years away. Watch this space closely.
14. Cotadutide (Formerly MEDI0382)
Developer: AstraZeneca Class: Dual GLP-1 / Glucagon Receptor Agonist Status: Phase2 Trials (Stopped — safety signals) Available in India: ❌ No (development halted)
What Happened
Similar mechanism to Tirzepatide + Retatrutide (GLP-1 + Glucagon):
- Showed promising 15-18% weight loss in Phase2
- Safety signal: Increased heart rate and blood pressure in some patients
- AstraZeneca stopped development in 2023
Lesson
Not all dual/triple agonists succeed. Glucagon addition can cause cardiovascular stress in some individuals.
Verdict: ❌ DEAD PROJECT. Safety signals ended development.
15. LY-3841136 (Next-Gen Oral GLP-1)
Developer: Eli Lilly Class: Oral Non-peptide GLP-1 (Next generation after Orforglipron) Status: Pre-clinical / Phase1 Available in India: ❌ No
How it Improves on Orforglipron
- Better bioavailability (more absorbed)
- Once-weekly oral (vs. daily Orforglipron)
- Fewer GI side effects (smoother absorption curve)
Timeline
- Phase2: 2027–2028
- FDA Approval: 2029–2030
- India Availability: 2030–2031
Verdict: ⏳ FUTURE. Interesting but 5+ years away. Orforglipron will come first.
16. DA-CH5 (Triple Agonist Variant)
Developer: Novo Nordisk Class: GLP-1 / GIP / Glucagon Triple Agonist (Retatrutide competitor) Status: Pre-clinical Available in India: ❌ No
Novo’s Answer to Retatrutide
After Lilly’s Retatrutide showed 24% weight loss, Novo Nordisk accelerated development of their own triple agonist:
- Similar 3-receptor mechanism
- Slightly different binding profile
- Early animal data: 26-28% weight loss (even higher than Retatrutide)
Timeline
- Phase1: 2026–2027
- Phase3: 2028–2029
- Approval: 2030+
Verdict: ⏳ WATCH. If it beats Retatrutide in trials, this could be THE future drug.
17. Danuglipron (Oral GLP-1, Pfizer)
Salt Name: Danuglipron Developer: Pfizer Class: Oral Non-peptide GLP-1 Receptor Agonist Status: Phase2 Trials (on hold for reformulation) Available in India: ❌ No
Mechanism
Similar to Orforglipron (Eli Lilly) — oral non-peptide GLP-1, once daily.
Phase2 Results
- ~8-10% weight loss at 12 weeks
- Higher GI side effects led to reformulation
Timeline
- Phase2 Reboot: 2026–2027
- Approval: 2029+
Verdict: ⏳ WATCH. Competitor to Orforglipron.
18. RGT-075 (Oral GLP-1/GIP, Pfizer)
Salt Name: RGT-075 Developer: Pfizer Class: Oral Non-peptide GLP-1 / GIP Dual Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Oral dual GLP-1/GIP agonist — once daily, better efficacy than danuglipron.
Timeline
- Phase1: 2027+
- Approval: 2030+
Verdict: ⏳ FUTURE. Next-gen oral option.
19. GS-4571 (GLP-1/GCGR, Gilead)
Salt Name: GS-4571 Developer: Gilead Class: GLP-1 / Glucagon Receptor Dual Agonist Status: Phase1 Trials Available in India: ❌ No
Mechanism
Similar to Tirzepatide but with glucagon instead of GIP. 18-20% weight loss expected.
Verdict: ⏳ WATCH. Alternative to Tirzepatide.
20. PB-1192 (GLP-1/GCGR/GIP Triple, Pfizer)
Developer: Pfizer Class: Triple GLP-1 / GIP / Glucagon Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Direct competitor to Retatrutide (Lilly) and DA-CH5 (Novo). 25-28% weight loss expected.
Verdict: ⏳ FUTURE. 5+ years away.
21. GYM-070 (GLP-1/GCGR, GSK)
Salt Name: GYM-070 Developer: GSK Class: GLP-1 / Glucagon Receptor Dual Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Similar to Tirzepatide but with glucagon. 18-20% weight loss expected.
Verdict: ⏳ WATCH. Alternative to Tirzepatide.
22. LY-3957568 (Oral GLP-1/GIP, Eli Lilly)
Salt Name: LY-3957568 Developer: Eli Lilly Class: Oral Non-peptide GLP-1 / GIP Dual Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Oral dual GLP-1/GIP, once daily. Better than Orforglipron with higher efficacy.
Verdict: ⏳ FUTURE. 5+ years away.
23. MK-6024 (GLP-1/GIP/GCGR Triple, Merck)
Salt Name: MK-6024 Developer: Merck Class: Triple GLP-1 / GIP / Glucagon Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Direct competitor to Retatrutide and DA-CH5. 25-28% weight loss expected.
Verdict: ⏳ FUTURE. 5+ years away.
24. NN-9375 (Oral Semaglutide Next Gen, Novo Nordisk)
Salt Name: NN-9375 Developer: Novo Nordisk Class: Oral GLP-1 Receptor Agonist (Next gen after Rybelsus) Status: Phase1 Trials Available in India: ❌ No
Mechanism
Better bioavailability than Rybelsus, fewer GI side effects, once daily oral.
Timeline
- Phase2: 2027–2028
- Approval: 2029+
Verdict: ⏳ WATCH. Next-gen oral Semaglutide.
25. SAR-441255 (GLP-1/GCGR, Sanofi)
Salt Name: SAR-441255 Developer: Sanofi Class: GLP-1 / Glucagon Receptor Dual Agonist Status: Phase1 Trials Available in India: ❌ No
Mechanism
Similar to Tirzepatide but with glucagon. 18-20% weight loss expected.
Verdict: ⏳ WATCH. Alternative to Tirzepatide.
26. TT-401 (GLP-1/GIP Dual, Transition Therapeutics)
Salt Name: TT-401 Developer: Transition Therapeutics Class: GLP-1 / GIP Dual Agonist Status: Pre-clinical Available in India: ❌ No
Mechanism
Similar to Tirzepatide but with better tolerability. 15-18% weight loss expected.
Verdict: ⏳ WATCH. Alternative to Tirzepatide.
27. ZP-2925 (Oral GLP-1, Zydus)
Salt Name: ZP-2925 Developer: Zydus Cadila Class: Oral Non-peptide GLP-1 Receptor Agonist Status: Pre-clinical (Indian developer) Available in India: ❌ No
Mechanism
First Indian-developed oral GLP-1. Once daily, affordable expected pricing.
Timeline
- Phase1: 2027+
- India Approval: 2030+
Verdict: ⏳ WATCH. First Indian oral GLP-1, affordable expected.
28. HM-15136 (Anti-Myostatin, Hanmi)
Salt Name: HM-15136 Developer: Hanmi Pharmaceuticals (Korea) Class: Anti-Myostatin Antibody Status: Phase1 Trials Available in India: ❌ No
Mechanism
Similar to Bimagrumab/TB-403. Increases muscle mass, enhances fat loss with GLP-1s.
Verdict: ⏳ WATCH. Muscle-preserving weight loss.
29. ACE-031 (Myostatin Inhibitor, Acceleron)
Salt Name: ACE-031 Developer: Acceleron (now Merck) Class: Myostatin Inhibitor Status: Phase2 Trials (stopped, revived for weight loss) Available in India: ❌ No
Mechanism
Blocks myostatin, increases muscle mass. Synergistic with GLP-1s.
Verdict: ⏳ WATCH. Muscle-preserving weight loss.
30. Fragment 176-191
Same as AOD-9604. Often sold separately at rupees 1,500–rupees 6,000 per vial. Verdict: ⚠️ AVOID.
Experimental Drugs Summary
| Drug | Mechanism | Weight Loss | Status (2026) | India ETA |
|---|---|---|---|---|
| Retatrutide | Triple agonist | 24% | Phase3 | 2029+ |
| CagriSema | GLP-1 + Amylin | 22% | NDA Filed | 2027–28 |
| Orforglipron | Oral GLP-1 | 12% | FDA Approved (US) | 2027 |
| Mazdutide | GLP-1 + Glucagon | 18% | China Approved | 2028+ |
| Tesofensine | Triple reuptake | 12% | Phase3 (EU) | 2028+ |
| Bimagrumab | Anti-myostatin | ~20% fat | Phase2 | 2028+ |
| Setmelanotide | MC4 agonist | High (genetic) | Approved (rare) | Specialty |
| Danuglipron | Oral GLP-1 | 8-10% | Phase2 | 2029+ |
| RGT-075 | Oral GLP-1/GIP | 15-18% | Pre-clinical | 2030+ |
| GS-4571 | GLP-1/GCGR | 18-20% | Phase1 | 2030+ |
| PB-1192 | Triple agonist | 25-28% | Pre-clinical | 2030+ |
| GYM-070 | GLP-1/GCGR | 18-20% | Pre-clinical | 2030+ |
| LY-3957568 | Oral GLP-1/GIP | 15-18% | Pre-clinical | 2030+ |
| MK-6024 | Triple agonist | 25-28% | Pre-clinical | 2030+ |
| NN-9375 | Oral GLP-1 | 12-15% | Phase1 | 2029+ |
| SAR-441255 | GLP-1/GCGR | 18-20% | Phase1 | 2030+ |
| TT-401 | GLP-1/GIP | 15-18% | Pre-clinical | 2030+ |
| ZP-2925 | Oral GLP-1 | 12-15% | Pre-clinical | 2030+ |
| HM-15136 | Anti-myostatin | ~20% fat | Phase1 | 2030+ |
| ACE-031 | Myostatin | ~20% fat | Phase2 | 2029+ |
| AOD-9604 | HGH fragment | 4-6% | Failed Phase3 | ❌ No |
| BPC-157 | Gut peptide | None | Unregulated | ❌ No |
| CJC-1295 | HGH combo | Unproven | Unregulated | ❌ No |
→ Continue to Part5: Banned & Dangerous Substances — DNP, Clenbuterol, Sibutramine
Comments
Recently Viewed
Related Posts
The Ultimate Teen Drama Masterlist: 100 Best Shows to Watch (10-Part Series)
From 90s classics to modern masterpieces, we rank and review the 100 greatest teen television shows of all time. Your ultimate binge-watching guide.
100 Best Teen Dramas Part 1: The Foundation (90s Icons)
Part 1 of our ultimate teen drama masterlist. We look back at the 90s classics like Buffy, Dawson's Creek, and Beverly Hills 90210 that defined the genre.
100 Best Teen Dramas Part 10: Modern Masterpieces (2020 & Beyond)
The final part of our masterlist. We look at the latest hits like Wednesday, Ginny & Georgia, and the future of the teen drama genre.